Compare · INMD vs STXS
INMD vs STXS
Side-by-side comparison of InMode Ltd. (INMD) and Stereotaxis Inc. (STXS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INMD and STXS operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- INMD is the larger of the two at $912.4M, about 4.8x STXS ($188.1M).
- Over the past year, INMD is up 1.0% and STXS is down 3.0% - INMD leads by 4.0 points.
- STXS has been more active in the news (6 items in the past 4 weeks vs 1 for INMD).
- INMD has more recent analyst coverage (20 ratings vs 6 for STXS).
- Company
- InMode Ltd.
- Stereotaxis Inc.
- Price
- $14.40+0.14%
- $1.94-0.77%
- Market cap
- $912.4M
- $188.1M
- 1M return
- +4.80%
- +3.47%
- 1Y return
- +1.02%
- -3.00%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- AMEX
- IPO
- 2019
- News (4w)
- 1
- 6
- Recent ratings
- 20
- 6
InMode Ltd.
InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies. The company offers minimally-invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. InMode Ltd. offers its products directly in United States, Canada, United Kingdom, Spain, India, Australia, and France, as well as through distributors in 47 countries. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was founded in 2008 and is headquartered in Yokneam, Israel.
Stereotaxis Inc.
Stereotaxis, Inc. designs, manufactures, and markets robotic magnetic navigation (RMN) systems for use in hospital's interventional surgical suite to improve the treatment of arrhythmias and coronary artery disease in the United States and internationally. Its RMN systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. Stereotaxis, Inc. markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was founded in 1990 and is based in St. Louis, Missouri.
Latest INMD
- InMode to Report First Quarter 2026 Financial Results and Hold Conference Call on May 6, 2026, Expects Q1 Revenue Between $81.5M-$81.7M, Reiterates FY 2026 Revenue Guidance Between $365M-$375M
- InMode to Present at the 25th Annual Needham Virtual Healthcare Conference
- SEC Form 3 filed by InMode Ltd.
- SEC Form 3 filed by InMode Ltd.
- SEC Form 3 filed by new insider Mizrahy Moshe
- SEC Form 3 filed by new insider Kreindel Michael
- SEC Form 3 filed by InMode Ltd.
- SEC Form 3 filed by InMode Ltd.
- SEC Form 3 filed by InMode Ltd.
- SEC Form 6-K filed by InMode Ltd.
Latest STXS
- Stereotaxis Announces First MAGiC Procedures in the United States
- Stereotaxis to Report First Quarter 2026 Financial Results on May 12, 2026
- Stereotaxis Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits
- Stereotaxis Announces Definitive Agreement to Acquire Robocath
- SEC Form 4 filed by Peery Kimberly R.
- Stereotaxis Announces FDA Clearance and Launch of Synchrony System
- Amendment: SEC Form 10-K/A filed by Stereotaxis Inc.
- SEC Form DEFA14A filed by Stereotaxis Inc.
- SEC Form DEF 14A filed by Stereotaxis Inc.
- SEC Form EFFECT filed by Stereotaxis Inc.